| Autor: |
Shaaban, Ingy Ossama Ahmed, Sultan, Hala K., Sultan, Magda M., El Gammal, Maha M. A., Balbaa, Ola A. |
| Předmět: |
|
| Zdroj: |
Egyptian Journal of Haematology; Apr-Jun2023, Vol. 48 Issue 2, p201-205, 5p |
| Abstrakt: |
Background Multiple myeloma (MM) is a clonal plasma cell disorder characterized by the abnormal increase of monoclonal paraprotein leading to specific end-organ damage. Drug resistance is one of the major challenges in treating MM. As an emerging cell adhesion-mediated drug resistance (CAM-DR) agent, JAM-A (Junctional adhesion molecule-A), represents an exciting new potential drug target and biomarker for treating MM. However, the pathological role and clinical relevance of JAM-A in MM remains ambiguous. Aim To study the relation of JAM-A expression levels in MM patients with possible prognostic factors. Patients and methods The study was carried out on a total of 100 subjects divided into two groups. The first group included 50 multiple myeloma patients, while the second group included 50 patients performing aspiration of bone marrow for other conditions with normal plasma cell percentage. All subjects in the current study were subjected to full history taking and complete clinical examination, radiological studies, routine laboratory investigations, bone marrow aspiration/biopsy, immunophenotyping, measurement of serum IL-6 levels and estimation of JAM-A expressions by Quantitative real-time PCR. Results JAM-A was overexpressed in newly diagnosed MM patients compared with post-treated patients and control group. Moreover, high JAM-A expression levels showed statistically significant correlations with plasma cell percentage in BM, serum ß2-microglobulin and serum IL-6 levels. Conclusion JAM-A is overexpressed in MM and could be used as innovative prognostic biomarker. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
